Does dextran 40 improve the early patency of autogenous infrainguinal bypass grafts?
Author: Katz S, Kohl R. Reference: J Vasc Surg 1998;28:23-7. Reviewer: Sergio Gregoretti, MD University of Alabama at Birmingham Birmingham, Alabama Introduction: Early occlusion is a significant problem after femorodistal bypass, occurring in 3-15% of cases. Although a technical error is often the culprit, it has been hypothesized that in some cases early graft failure is caused by a “hypercoagulable” state described in these patients postoperatively. Initial reports have suggested that low molecular weight dextran (dextran 40), with its well known antithrombotic properties, may increase the early patency of lower extremity bypass grafts. The authors performed this prospective, randomized study to determine the role of dextran 40 in the early outcome of autogenous vein bypass grafts for lower extremity revascularization. Methods: Patients undergoing infrainguinal bypass surgery using reversed vein grafts were randomized to a dextran-treatment or to a no-treatment, control group. Exclu
Related Questions
- What are the early outcomes of percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass grafting (CABG) in patients with two- and three-vessel coronary artery disease?
- Does dextran 40 improve the early patency of autogenous infrainguinal bypass grafts?
- Does renal failure influence infrainguinal bypass graft outcome?
